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Abstract 
Background: Several null‑mutations in the FLG gene that produce a decrease or absence of filaggrin in the skin and 
predispose to atopic dermatitis and ichthyosis vulgaris have been described. The relationship with asthma is less clear 
and may be due to the influence of atopy in patients with associated asthma.
Methods: Four hundred individuals were included, 300 patients diagnosed with asthma divided into two groups 
according to their phenotype (allergic and non‑allergic asthma) and 100 strictly characterized controls. The coding 
region and flanking regions of the FLG gene were amplified by PCR. We proceeded to the characterization of potential 
gene variants in that region by RFLP and sequencing and analysed their association with lung function parameters, 
asthma control and severity, and quality of life.
Results: We identified two null‑mutations (R501X and 2282del4), seven SNPs previously described in databases and 
three SNPs that had not been previously described. One of the SNP identified in this study (1741A > T) was more fre‑
quently detected in patients with non‑allergic asthma, worse FVC, FEV1 and PEF values and a higher treatment step. 
In addition, lowered spirometric values were observed in the non‑allergic group carrying any of the nonsynonymous 
SNPs.
Conclusions: In the association study of genetic variants of the FLG gene in our population the 1741A > T polymor‑
phism seems to be associated with non‑allergic asthma.
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Background
“Atopic march” theory suggests that children with atopic 
predisposition may suffer various diseases throughout 
their life such as atopic dermatitis, rhinitis or asthma and 
can become sensitised to various allergens. With regard 
to aeroallergen sensitization it may manifest as allergic 
rhinoconjunctivitis and, in a proportion of subjects, as 
asthma [1].
Filaggrin is a key protein in the differentiation of the 
epidermis and the formation of the stratum corneum of 
the skin, the outermost layer of the skin, essential to pre-
vent water loss through the epidermis and to avoid the 
entry of allergens, toxic chemicals and germs [2]. This 
protein is composed of 324 amino acids, has a molecular 
weight of 37  kDa and it corresponds to 6  % of the epi-
dermis protein content. Filaggrin assists the binding of 
keratin filaments of the skin, hence its name (FILament 
AGGregation proteIN). Profilaggrin, which contains 
10–12 tandemly repeated filaggrin units and is processed 
into filaggrin by specific dephosphorylation and prote-
olysis during terminal differentiation of the epidermal 
cells, is encoded by the FLG gene. This gene is located on 
the long arm of chromosome 1 at position 1q21.3, and 
it is located in the so-called EDC (epidermal differentia-
tion complex) region, which brings together a group of 
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more than 30 structural and evolutionarily related genes, 
which encode proteins of the epidermis, such as filag-
grin, loricrin or involucrin, among others. Several stud-
ies using biopsies from various tissues had observed that 
filaggrin is also expressed in the oral mucosa, the tongue 
and in the nasal mucosa, where it is assumed that it also 
contributes to the barrier function [3–6]. Although in 
some studies protein expression could not be detected 
in nasal [4], oesophageal [4] or bronchial [7] mucosa, 
gene expression studies indexed in GeneCards® (http://
www.genecards.org) show that FLG gene expression was 
observed in lung and bronchial epithelium.
There are reports of various null-mutations in the FLG 
gene (R501X, 2282del4 and subsequently others) that 
produce a decrease or absence of filaggrin in the skin 
and predispose to ichthyosis vulgaris [8, 9] and atopic 
dermatitis [9–19]. It has been identified that heterozy-
gous patients for one of the mutations have no discern-
ible phenotype or may have a minor ichthyosis, while 
homozygous mutant and heterozygous combinations 
(heterozygous for the two mutations) show marked ich-
thyosis with an obvious histological defect of the skin 
barrier [8]. All these mutations and their relationship to 
asthma is not so clear [10–26] and it could be that the 
relationship found in some studies is due to the influ-
ence of eczema or atopic dermatitis in subjects who 
have asthma associated with these skin diseases [27, 28], 
although, for the moment, studies to assess their rela-
tionship in the phenotypes of allergic and non-allergic 
asthma [26] are scarce.
The aim of our study was to assess whether the associa-
tion identified in some studies in connection with asthma 
might not be due directly to this disease but to any of the 
associated phenotypes and therefore we designed a study 
with two patient groups with well differentiated asthma 
phenotypes. In addition, we sought to assess the exist-
ence of other gene variants in that region, responsible for 
the association with some of the clinical and biological 
characteristics of patients with asthma.
Methods
This was a descriptive, cross-sectional, observational 
study carried out in Spain.
Ethics statement
All subjects included in the study were adults and gave 
their agreement by signing an informed consent. The 
study was approved by the local health authority and it´s 
Ethics Committee.
Subjects
A total of 400 individuals were included: 300 Caucasian 
not related patients from the University Hospital Lozano 
Blesa (Zaragoza, Spain) diagnosed with asthma accord-
ing to the GINA criteria (global initiative for asthma) 
[29] that came for consultations from July 2008 to August 
2009 and 100 Spanish Caucasian controls from the Uni-
versity Hospital of Salamanca (Salamanca, Spain).
The required sample size calculation (statistical power 
of 80  % and significance level of 5  %) was calculated 
using the allelic frequencies obtained by Palmer et  al. 
[21] eighty-five subjects in the control group (allelic fre-
quency 0.01) and 256 patients in the asthma group (allelic 
frequency 0.10) for R501X null-mutation and 67 subjects 
in control group (allelic frequency 0.02) and 200 patients 
in asthma group (allelic frequency 0.14) for 2282del4 
null-mutation.
Patients were divided into two groups with the follow-
ing inclusion criteria:
  • Non-allergic asthma (NA): 150 patients diagnosed 
with asthma (compatible clinical history, obstruc-
tive spirometry with a bronchodilator test with an 
increase of ≥12  % and ≥200  mL in FEV1 (forced 
expiratory volume in 1 s) or bronchial hyper-respon-
siveness test with methacholine), with negative skin 
tests with standard battery of common inhalant aller-
gens in our environment and no symptoms upon 
exposure to allergens.
  • Allergic asthma (AA): 150 patients diagnosed with 
asthma (same criteria as for NA), positive skin tests 
to any aeroallergen(s) in the standard battery for our 
environment and clinically relevant and symptoms 
upon exposure.
In addition, 100 healthy controls (HC) where chosen, 
who had to meet the following inclusion criteria: no his-
tory of atopy, asthma or chronic respiratory diseases, no 
family history of asthma or atopy and negative skin tests 
to a local airborne allergen battery.
The exclusion criteria were: age <18  years (to meet 
the local health authority and Ethics Committee legal 
requirements) or non-Caucasian or non-Spanish 
population.
Variables analysed
Family history of atopy and personal history of atopic 
dermatitis, contact dermatitis, food allergy, drug allergy, 
hypersensitivity to non-steroidal anti-inflammatory 
drugs (NSAIDs), psoriasis or ichthyosis vulgaris were 
assessed. The presence of rhinitis, chronic rhinosinusitis, 
nasal polyps or anosmia was also evaluated.
Skin prick tests were performed with the battery of 
common airborne allergens in our environment (Phleum 
pratense, Cynodon dactylon, Olea europaea, Parietaria 
judaica, Chenopodium album, Salsola kali, Platanus 
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acerifolia, Cupressus sempervirens, Alternaria alternata, 
Cladosporium herbarum, Aspergillus fumigatus, Der-
matophagoides pteronyssinus, Tyrophagus putrescentiae, 
Lepydoglyphus destructor and dog and cat dander). His-
tamine hydrochloride (10  mg/mL) and glycerol saline 
served as positive and negative controls, respectively. A 
skin test was considered positive when its larger diameter 
was ≥3 mm than the negative control. The value of the 
total Immunoglobulin E (IgE) was determined.
The nature and severity of asthma was assessed by the 
values of forced spirometry: FEV1 (forced expiratory 
volume in 1  s), FVC (forced vital capacity), PEF (forced 
expiratory flow), MMEF (maximal mid-expiratory flow) 
and post-bronchodilator FEV1 improvement; exhaled 
nitric oxide (FeNO); personal history of occupational 
asthma or asthma worsened in the workplace; asthma 
severity and treatment step according to GINA [29]; min-
iAQLQ quality of life questionnaire (mini asthma qual-
ity of life questionnaire) [30], a shorter version of AQLQ 
(asthma quality of life questionnaire) also validated in 
Spanish [31]; and the ACT asthma control questionnaire 
(asthma control test) [32] validated in Spanish [33].
Genetic analysis
For the molecular analysis, genomic DNA was obtained 
from whole blood of each individual, by a standard pro-
cedure using the automated Maxwell 16 DNA extraction 
system (Promega, Madison, Wisconsin, USA).
The 1102  bp flanking fragment from the FLG gene 
regions of interest was amplified by PCR using the 
extracted genomic DNA and FilH1F3 and RPT2P1 prim-
ers described by Smith et  al. [8]. The determination of 
these mutations was performed using two methods:
  • For the R501X mutation a sequencing study was 
carried out in a 3100 genetic analyzer (Applied Bio-
systems, CA, USA) automatic sequencer, using the 
aforementioned oligonucleotides for PCR reactions. 
The sequencing study allowed us to analyse this 
region and detect new SNPs. The Genbank accession 
number for the reference genomic sequence used for 
FLG was NG_016190.1. The analysis was performed 
blind with respect to case-status monitoring.
  • For the 2282del4 mutation a RFLP analysis by diges-
tion with the DraIII restriction enzyme was per-
formed. Results of the respective digestions were 
visualized in a 1 % agarose gel-red stained gel in TBE 
buffer. The presence of the mutated allele (deletion 
of 4 amino acids) involved the appearance of a new 
restriction target and electrophoresis display of two 
fragments 962 and 136 pb.
In silico analysis
The in silico analysis was performed using the following 
programs:
ChromasLite version 2.01 (Technelysium Pty Ltd, Bris-
bane, Australia), Vector NTI 10 (Invitrogen, Carlsbad, 
California, USA), OMIM® (http://www.ncbi.nlm.nih.gov/
omim), dbSNP of the NCBI (http://www.ncbi.nlm.nih.
gov/snp).
The prediction analysis of polymorphisms functional 
effect was carried out by online platforms ExPASyProSite 
(http://www.expasy.org/), SNPeffect 4.0 (http://snpeffect.
switchlab.org/) and PolyPhen-2 prediction of functional 
effects of human nsSNPs (http://genetics.bwh.harvard.
edu).
Statistical analysis
The descriptive, bivariate and multivariate analysis was 
performed using SPSS version 15.0 (Chicago, Illinois, 
USA).
Genotype, allele and haplotype frequencies were com-
pared in the study and control populations by the SHEsis 
online statistical platform (http://analysis.bio-x.cn/myA-
nalysis.php).
Hardy–Weinberg equilibrium was tested by a χ2 test 
(Pearson’s p value). Bivariate analysis used analysis of 
variance to compare continuous outcomes across the 
levels of each genotype. Dichotomous variables were 
analyzed using χ2, Fisher’s exact test, Monte Carlo simu-
lation after 104 iterations and odds ratio test (95 % con-
fidence interval) for comparisons of the distribution 
of categorical variables. A non parametric test such as 
Kruskall–Wallis was applied for non normal distribu-
tions. Logistic Regression was used to model the effects 
of multiple covariates on the continuous and dichoto-
mous outcomes. Age and sex were included as poten-
tial covariates in multivariate analysis. A p value of less 
than 0.05 was considered statistically significant. To cor-
rect for multiple comparisons Bonferroni correction was 
applied. Considering that in some cases a much lower p 
value based on multiple comparison corrective proce-
dures would result in unnecessarily low power, the false 
positive report probability (FPRP) is provided. The FPRP 
depends on the prior probability π of a true association 
of the tested association, the α level or observed p-value, 
and the statistical power to detect the odds ratio of the 
alternative hypothesis at the given α level or p value. Sta-
tistical power is based on sample size, frequency of the 
at-risk genetic variant, and the specified odds ratio for 
the presumed association under the alternative hypoth-
esis [34]. A statistical power near 80 % for α error of 0.05 
was considered.
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Results
Study population
The mean age of the study group was 47.9 ± 17.9 years 
(36.2 ± 13.2 in AA, 56.9 ± 15.8 in NA and 52.1 ± 17.5 
in HC) with significant differences between groups 
[p < 0.001 between the 3 groups, p = 0.007 between HC 
and All Asthma group (46.5 ± 17.9 years) and p < 0.001 
between AA and NA]. There were 40.5  % men in the 
study sample (53.3  % in AA, 32.0  % in NA and 34.0  % 
in HC) with significant differences between groups 
[p  <  0.001 between the 3 groups, p  >  0.05 between all 
asthma group (42.7  %) and HC and p  <  0.001 between 
AA and NA].
In AA, 21.3 % skin tests were positive only to seasonal 
allergens (pollens), 15.3 % for perennial allergens (mites, 
moulds and dander) and 65.3  % for both seasonal and 
perennial allergens. The median number of positive skin 
tests was 6.0 (interquartile range 4.0). Total IgE mean was 
189.6 ± 384.6 IU/mL (379.8 ± 535.8 in AA, 68.6 ± 117.7 
in NA and 86.0  ±  235.2 in HC) with significant differ-
ences between groups [p < 0.001 between the 3 groups, 
p  <  0.001 between all asthma group (224.2 ±  417.4  IU/
mL) and HC and p < 0.001 between AA and NA].
Family and personal history are shown in Table 1. There 
were significant differences between groups in all of them 
except in the history of psoriasis and ichthyosis vulgaris.
Subjects suffering from rhinitis constituted the 87 % of 
the total asthmatic patients, 94 % in the case of AA and 
80 % for the NA group (p < 0.05). In the NA group 52 % 
of patients had chronic rhinosinusitis. A greater propor-
tion of nasal polyposis (28 vs 6 %) and anosmia (16.7 vs 
8 %) was found in the NA group (p < 0.05).
Significant differences were observed in spirometry val-
ues (except post-bronchodilator improvement) as well as 
the value of FeNO. See Table 1. However, no significant 
differences were found in the value of the miniAQLQ or 
ACT.
Classifying the severity of asthma according to the 
GINA guidelines, 2.7  % had intermittent asthma (4.7  % 
in AA and 0.7  % in NA), 9.0  % mild persistent asthma 
(12.7 % in AA and 5.3 % in NA), 81.7 % moderate persis-
tent asthma (80.7 % in AA and 82.7 % in NA) and 6.7 % 
severe persistent asthma (2.0 % in AA and 11.3 % in NA). 
Significant differences between groups (p  <  0.001) were 
observed.
R501X and 2282of4 mutations
The genotype and allele frequencies of R501X and 
2282del4 mutations can be seen in Table 2. All subjects 
carried heterozygous mutations. No combined heterozy-
gote patient was identified.
In our study we found no association between filag-
grin R501X and 2282del4 mutations and the presence of 
asthma assessed globally or by its two phenotypes. Nor 
were significant differences found in the personal history 
for sinonasal disease, spirometry values, FeNO, severity of 
asthma according to the GINA guidelines, treatment step 
according to the GINA guidelines, miniAQLQ or ACT.
Table 1 Clinical characteristics, lung function values and FeNO of the patients included in the study
AA Allergic Asthma group, NA Non-allergic Asthma group, NSAID non-steroidal anti-inflammatory drugs, FVC Forced Vital Capacity, FEV1 Forced Expiratory Volume in 
1 s, PEF forced expiratory flow, MMEF maximal mid-expiratory flow, FeNO exhaled nitric oxide
* p < 0.05
All asthmatic  
patients (n = 300)
AA (n = 150) NA (n = 150)
Family history of atopy (%)* 120 (40.0 %) 74 (49.3 %) 46 (30.7 %)
Atopic dermatitis (%)* 15 (5.0 %) 14 (9.3 %) 1 (0.7 %)
Contact dermatitis n (%) 73 (24.3 %) 34 (22.7 %) 39 (26.0 %)
Food allergy (%)* 32 (10.7 %) 28 (18.7 %) 4 (2.7 %)
Drug allergy (%)* 58 (19.3 %) 19 (12.7 %) 39 (26.0 %)
Hypersensitivity to NSAID (%)* 34 (11.3 %) 6 (4.0 %) 28 (18.7 %)
Psoriasis (%) 4 (1.3 %) 2 (1.3 %) 2 (1.3 %)
Ichthyosis vulgaris (%) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Lung function values mean ± SD
 FVC (%)* 97.2 ± 16.0 100.9 ± 13.0 93.6 ± 17.9
 FEV1 (%)* 93.0 ± 17.5 96.4 ± 14.2 89.7 ± 20.0
 FEV1/FVC* 74.7 ± 8.6 76.3 ± 8.0 73.0 ± 8.8
 Post‑bronchodilator FEV1 improvement (%) 12.81 ± 9.2 12.56 ± 8.5 13.1 ± 9.8
 PEF (%)* 95.0 ± 20.7 99.7 ± 18.2 90.3 ± 22.0
 MMEF (%)* 63.4 ± 25.7 69.8 ± 21.1 57.1 ± 28.3
 FeNO (ppb) mean ± SD* 32.3 ± 30.8 38.0 ± 35.3 26.6 ± 24.2
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New SNPs
An SNP search was performed in the sequenced frag-
ment to study the R501X mutation in the 1.102pb frag-
ment amplified by PCR.
Three novel polymorphisms not previously described 
were identified for the first time in this genomic region 
(1594C  >  T, 1607T  >  A and 1747C  >  A). These three 
polymorphisms located in the exon region also generate 
changes in the encoded amino acid (see Table 3).
In addition, in our population another 7 polymor-
phisms were detected that were previously described 
but which had not been analysed in asthmatic patients 
(1494G  >  C, 1560G  >  A, 1603T  >  C, 1632C  >  T, 
1676A > G, 1741A > T y 1807G > A). See Table 3.
SNP 1741A  >  T was identified in five individuals 
(1.25 % of our population), the rest only in one (0.25 % of 
our population). The genotype frequencies of SNP can be 
seen in Table 2. No subject simultaneously carried more 
Table 2 Genotype frequencies of the 12 SNPs identified in our population
HC Healthy Controls group, AA Allergic Asthma group, NA Non-allergic Asthma group
a N normal allele, unmutated. D deleted allele
Total HC AA NA All asthmatic patients
n 400 100 150 150 300
R501X CC 0.98 0.98 0.98 0.99 0.99
CT 0.02 0.02 0.02 0.01 0.01
TT 0.00 0.00 0.00 0.00 0.00
2282del4 NNa 0.99 0.99 1.00 0.99 1.00
NDa 0.01 0.01 0.00 0.01 0.00
DDa 0.00 0.00 0.00 0.00 0.00
1741A > T AA 1.00 0.99 1.00 0.97 0.99
AT 0.00 0.01 0.00 0.03 0.01
TT 0.00 0.00 0.00 0.00 0.00
1494G > C GG 1.00 0.99 1.00 1.00 1.00
GC 0.00 0.01 0.00 0.00 0.00
CC 0.00 0.00 0.00 0.00 0.00
1560G > A GG 1.00 0.99 1.00 1.00 1.00
GA 0.00 0.01 0.00 0.00 0.00
AA 0.00 0.00 0.00 0.00 0.00
1594C > T CC 1.00 1.00 1.00 0.99 1.00
CT 0.00 0.00 0.00 0.01 0.00
TT 0.00 0.00 0.00 0.00 0.00
1603T > C TT 1.00 1.00 1.00 0.99 1.00
TC 0.00 0.00 0.00 0.01 0.00
CC 0.00 0.00 0.00 0.00 0.00
1607T > A TT 1.00 1.00 0.99 1.00 1.00
TA 0.00 0.00 0.01 0.00 0.00
AA 0.00 0.00 0.00 0.00 0.00
1632C > T CC 1.00 1.00 1.00 0.99 1.00
CT 0.00 0.00 0.00 0.01 0.00
TT 0.00 0.00 0.00 0.00 0.00
1676A > G AA 1.00 1.00 0.99 1.00 1.00
AG 0.00 0.00 0.01 0.00 0.00
GG 0.00 0.00 0.00 0.00 0.00
1747C > A CC 1.00 1.00 0.99 1.00 1.00
CA 0.00 0.00 0.01 0.00 0.00
AA 0.00 0.00 0.00 0.00 0.00
1807G > A GG 1.00 1.00 0.99 1.00 1.00
GA 0.00 0.00 0.01 0.00 0.00
AA 0.00 0.00 0.00 0.00 0.00
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than one variation from the 12 SNPs studied. None of the 
15 patients with a history of atopic dermatitis were carri-
ers of any of the 12 SNP studied.
1741A > T
SNP 1741A  >  T (rs145627745) is found in genomic 
position 1741 and is an adenine-to-thymine transver-
sion. The protein carries a modification in position 581, 
where the amino acid threonine (Thr) changes to a serine 
(Ser), so this SNP can also be designated as p.T581S or 
p.Thr581Ser. This change is present in 5 subjects, 4 of the 
NA group (2.67 %) and 1 of the HC (1.0 %). The genotype 
and allele frequencies are reflected in Table 2. No statis-
tically significant differences were found when analysing 
age or gender differences, indicating the absence of a bias 
based on such variables.
We identified a statistically significant association 
between the asthma phenotype and 1741A > T, being the 
most common mutated allele in patients with non-aller-
gic asthma (genotypic p =  0.044 and allelic p =  0.045). 
See Table  4. However, no association was identified 
between 1741A  >  T and the presence of both overall 
asthma and asthma worsened in the workplace or occu-
pational asthma.
When analysing the values of forced spirometry we 
found a statistically significant association between 
1741A > T and FVC (p = 0.006), FEV1 (p = 0.020) and 
PEF (p  =  0.002) (see Table  5), confirmed by logistic 
regression adjusted by sex and age. No statistically sig-
nificant associations were observed with FeNO.
No statistically significant association in the severity 
of asthma was observed according to the GINA guide-
line and 1741A > T, but there were differences in the 
treatment step according to that guideline (p = 0.004): 
step one 3.3 vs 0  %, step two 9.0 vs 0  %, step three 
56.7 vs 0 %, step four 27.7 vs 1.0 % and step five 2.0 vs 
0.3 %, confirmed by logistic regression adjusted by sex 
and age.
The analysis using the ExPASyProsite platform of the 
functional change produced by this SNP indicates that it 
is located exactly on a myristoylation site that could have 
an impact on the protein’s activity. According to the anal-
ysis conducted by SNPeffect this SNP does not affect the 
amyloid, binding to chaperones or aggregation tendency. 
In the study of functional prediction by PolyPhen-2 pre-
diction of functional effects of human nonsynonymous 
SNPs we observed a score of 0.083 (sensitivity: 0.93; 
specificity: 0.85).
Table 3 SNPs found in our population
SNP Single-Nucleotide Polymorphism
a Obtained from dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/)
SNP Referencea SNP Protein change Global minor 
allele frequencya
1494G > C p.E498D rs13376095 G/C Glu → Asp 0.0068
1560G > A p.P520P rs369161171 G/A Pro → Pro –
1594C > T p.H532Y C/T His → Tyr
1603T > C p.S535P rs74129464 T/C Ser → Pro 0.0154
1607T > A p.V536E T/A Val → Glu
1632C > T p.S544S rs137997325 C/T Ser → Ser 0.0020
1676A > G p.H559R rs546475787 A/G His → Arg 0.0004
1741A > T p.T581S rs145627745 A/T Thr → Ser 0.0030
1747C > A p.H583 N C/A His → Asn
1807G > A p.V603 M rs137995883 G/A Val → Met 0.0010
Table 4 Allele and genotype frequencies of 1741A > T SNP in allergic and non-allergic asthma
HC Healthy controls group, AA Allergic asthma group, NA Non-allergic asthma group
* Fisher’s p < 0.05
Genotype frequency 1741A > T Allele frequency 1741A > T
AA AT TT p A T p
HC (n = 100) vs All Asthma (n = 300) 0.99 (n = 99)
0.99 (n = 296)
0.01 (n = 1)
0.01 (n = 4)
0.00 (n = 0)
0.00 (n = 0)
0.79 0.99 (n = 99)
0.99 (n = 296)
0.01 (n = 1)
0.01 (n = 4)
0.80
AA (n = 150) vs NA (n = 150)* 1.00 (n = 150)
0.97 (n = 146)
0.00 (n = 0)
0.03 (n = 4)
0.00 (n = 0)
0.00 (n = 0)
0.044 1.00 (n = 0)
0.99 (n = 146)
0.00 (n = 0)
0.01 (n = 4)
0.045
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Considering the scarce representation of FLG mutant 
alleles a combined variable using all the nonsynonymous 
SNPs was created. Significant association was detected 
between mutant alleles and FVC (p  =  0.011), FEV1 
(p  =  0.001), FEV1/FVC (p  =  0.019), PEF (p  =  0.002), 
MMEF (p  =  0.007) as well as lower total IgE levels 
(p  =  0.028), see Table  6. These findings are also found 
in the non-allergic group for FVC (p  =  0.002), FEV1 
(p = 0.002), PEF (p = 0.014) and MMEF (p = 0.029) and 
in the allergic group only for FEV1/FVC (p = 0.034). This 
was confirmed by logistic regression adjusted by sex and 
age except total IgE.
Discussion
In this study, the R501X and 2282del4 mutations were 
not identified as being associated with any of the patients’ 
clinical and biological characteristics. It is noteworthy 
that the allele frequencies of these mutations in our pop-
ulation were lower than those obtained in European pop-
ulation studies [10, 21]. This could be due to the inclusion 
criteria of the study, but may also indicate particular 
aspects of the Spanish population.
In this study we identified for the first time three poly-
morphisms that had not been previously described in the 
filaggrin gene (1594C > T, 1607T > A and 1747C > A). It 
is very interesting to note that one of the polymorphisms 
identified in this work, 1741A > T, showed an association 
with non-allergic asthma and with a greater severity of it. 
In our series, none of the patients with personal history 
of atopic dermatitis were carriers of any of the 12 identi-
fied SNPs.
Mutations in the filaggrin gene have shown great 
importance in ichthyosis vulgaris [8] and atopic der-
matitis [9–19], but no clear relationship to asthma has 
been deduced [10–26]. There is a considerable contro-
versy about the possible association with asthma and it 
is unclear whether the association detected in some stud-
ies is due to the presence of asthma or the influence of 
eczema or atopic dermatitis in individuals who have 
asthma associated with these skin diseases, as two meta-
analyses concluded [27, 28].
We found statistically significant differences in 
SNP 1741A  >  T when analysing the spirometry val-
ues: patients carrying the T allele presented lower 
FVC, FEV1 and PEF values than those carrying the 
A allele. We also found statistically significant differ-
ences when analysing the treatment step required by 
patients according to GINA guidelines, requiring a step 
higher than 3 the patients carrying the T allele. Some 
mutations in the FLG gene have been associated with 
the presence of asthma (in particular allergic asthma 
and asthma with atopic dermatitis). Despite hav-
ing been described in the databases this SNP has not 
been studied in populations of patients with atopic 
dermatitis or asthma. Interestingly, in our population 
it was associated to non-allergic asthma. Gene expres-
sion studies indexed in GeneCards® (http://www.gen-
ecards.org) show that the FLG gene expression was 
observed in lung and bronchial mucosa, despite of the 
Table 5 Spirometry and exhaled nitric oxide values in patients with non-allergic asthma, according to the 1741A > T SNP
FVC Forced Vital Capacity, FEV1 Forced Expiratory Volume in 1 s, PEF forced expiratory flow, MMEF maximal mid-expiratory flow, FeNO exhaled nitric oxide
* p < 0.05
Average per genotype 1741A > T
AA (n = 296) mean ± SD AT (n = 4) mean ± SD p
FVC (%)* 97.5 ± 15.8 75.3 ± 13.7 0.006
FEV1 (%)* 93.3 ± 17.4 72.9 ± 9.5 0.020
FEV1/FVC 74.8 ± 8.6 69.2 ± 7.3 0.20
Post‑bronchodilator FEV1 improvement (%) 12.8 ± 9.2 13.1 ± 5.8 0.94
PEF (%)* 95.5 ± 20.5 63.5 ± 8.0 0.002
MMEF (%) 63.8 ± 25.7 38.9 ± 14.3 0.055
FeNO (ppb) 32.3 ± 30.9 34.0 ± 24.3 0.91
Table 6 Associations of  combined variable using all the 
nonsynonymous SNPs
FVC Forced Vital Capacity, EV1 Forced Expiratory Volume in 1 s, PEF forced 
expiratory flow, MMEF maximal mid-expiratory flow, FeNO exhaled nitric oxide, 
IgE Immunoglobulin E
Mutant alleles No mutant alleles p
FVC (%) (n = 15 vs 285) 87.9 ± 19.2 97.7 ± 15.7 0.011
FEV1 (%) (n = 15 vs 285) 80.5 ± 19.1 93.7 ± 17.1 0.001
FEV1/FVC (n = 15 vs 285) 70.6 ± 9.7 74.9 ± 8.5 0.019
PEF (%) (n = 15 vs 285) 81.3 ± 22.5 95.8 ± 20.4 0.002
MMEF (%) (n = 15 vs 285) 48.8 ± 21.7 64.3 ± 25.7 0.007
Total IgE (IU/mL) (n = 20 
vs 380)
120.3 ± 255.7 193.7 ± 390.6 0.028
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lack of protein detection in such mucosa [7]. In addi-
tion, filaggrin is expressed in oral mucosa, where it is 
assumed that it also contributes to the barrier func-
tion [3, 4]. It has also been shown to be expressed in 
the nasal vestibule up to the transitional epithelium 
[5] and, very recently, in the nasal mucosa [6]. The 
link between upper and lower airways and the relation 
between asthma and nasal polyposis are well known 
[35] and this could be related to the association found 
between 1741A  >  T SNP and non-allergic asthma, as 
2 of the 4 non-allergic asthmatic patients carrying the 
SNP had chronic rhinosinusitis. Nevertheless, in our 
study none of them had a personal history of nasal pol-
yps, although this entity is frequently infradiagnosed. 
The epithelium plays an important role in the incep-
tion and development of asthma, particularly in non-
allergic asthma, through the activation of type 2 innate 
lymphoid cells (ILC2) [36] and SNPs in filaggrin could 
compromise skin barrier function, increase penetra-
tion of allergens, reduce inflammatory threshold lev-
els to skin irritants and allergens and increase the risk 
of sensitization [37]. It is tempting to speculate that 
microbes, pollutants, tobacco smoke or other factors 
could easier cross the epithelial barrier and induce the 
inflammatory process in allergic asthma but maybe also 
in non-allergic asthma.
This SNP generates a change from threonine to serine 
in the filaggrin protein. While the predicted level of path-
ogenicity for this SNP is not very high, we have identified 
that this change is found in a pattern of myristoylation 
of the protein. Myristoylation of proteins occurs when 
there is a transfer of a myristoyl group to the glycine 
amino group of a specific protein sequence, using Myr-
CoA as substrate. It is assumed that myristoylation is an 
irreversible process that occurs co-translationally. In fact, 
myristoylation of proteins increases their hydrophobicity 
and thus could have a functional impact not described to 
date. More analysis of the protein produced in patients 
carrying the T allele are needed.
Nine other polymorphisms have been described; three 
of them (1594C  >  T, 1607T  >  A and 1747C  >  A) have 
been described for the first time in this study. Neverthe-
less, no clinical associations were identified, perhaps due 
to the low frequency of occurrence, at least in our pop-
ulation. Considering the scarce representation of FLG 
mutant alleles a combined variable using all the nonsyn-
onymous SNPs was created. This approach has been used 
in the field of FLG mutations due to their low frequency. 
A significant association was detected between carrying 
mutant alleles and worse respiratory function values in 
non-allergic asthma.
We think it is important to point out that our study was 
prepared from the outset to assess the influence of these 
mutations and SNPs in the filaggrin gene in asthma and 
potential importance of atopy in this association. There-
fore, we included asthmatic patients divided into two 
groups with well-differentiated AA and NA phenotype 
and solid clinical classifications, and a control group rig-
orously selected without personal or family history of 
atopy. Our results are consistent with several studies in 
other populations that question the association of muta-
tions in the FLG gene and asthma [10, 14, 17, 20], but 
interestingly in our study the association seems to be with 
non-allergic asthma without eczema or atopic dermatitis. 
In this sense, it could be interesting to interrogate possible 
differences regarding filaggrin expression in the bronchial 
mucosa between allergic and non allergic asthma to assess 
implication of SNPs in the filaggrin gene.
In our population, we detected no association for any 
of the variants of the FLG gene analysed with atopic 
dermatitis or with any other clinical variable, possibly 
because our patients, unlike those of other studies, were 
selected due to presenting asthma and not dermatitis as 
initial clinical variable, making them a distinct popula-
tion. In this respect this result would indicate the exist-
ence of distinct genetic associations for both diseases and 
again could explain the contradictory results obtained in 
the literature.
In conclusion, in our population we found no sig-
nificant differences with null-mutations R501X and 
2282del4, but we did find significant differences with SNP 
previously described in the FLG gene but which has not 
been studied in patient populations. In addition, we have 
first identified three polymorphisms that had not been 
previously described in FLG gene (1594C > T, 1607T > A 
and 1747C > A).
Conclusions
In the association study of genetic variants of the FLG 
gene in our population the 1741A  >  T polymorphism 
seems to be associated with non-allergic asthma.
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